Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) have been given a consensus rating of “Buy” by the eight research firms that are covering the stock, Marketbeat.com reports. Eight research analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $10.00.
Several equities analysts have recently weighed in on CMPX shares. LADENBURG THALM/SH SH assumed coverage on shares of Compass Therapeutics in a report on Tuesday, March 15th. They set a “buy” rating and a $7.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of Compass Therapeutics in a report on Monday, May 23rd.
In related news, CEO Thomas J. Schuetz acquired 27,836 shares of the stock in a transaction that occurred on Tuesday, May 10th. The stock was purchased at an average price of $1.80 per share, with a total value of $50,104.80. Following the transaction, the chief executive officer now owns 5,153,303 shares of the company’s stock, valued at approximately $9,275,945.40. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Thomas J. Schuetz acquired 18,355 shares of the stock in a transaction that occurred on Monday, May 23rd. The shares were bought at an average cost of $2.72 per share, with a total value of $49,925.60. Following the transaction, the chief executive officer now directly owns 5,191,873 shares in the company, valued at approximately $14,121,894.56. The disclosure for this purchase can be found here. In the last three months, insiders bought 342,525 shares of company stock valued at $725,478.
NASDAQ:CMPX opened at $2.13 on Wednesday. The company has a 50 day moving average price of $2.10 and a 200-day moving average price of $2.02. Compass Therapeutics has a 1-year low of $1.25 and a 1-year high of $5.80.
Compass Therapeutics (NASDAQ:CMPX – Get Rating) last posted its earnings results on Monday, May 9th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.07. Analysts expect that Compass Therapeutics will post -0.35 earnings per share for the current fiscal year.
About Compass Therapeutics (Get Rating)
Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, develops proprietary antibody-based therapeutics to treat multiple human diseases. The company's product candidates include CTX-009, an investigational bispecific antibody, which is in Phase II clinical trial for biliary tract cancers, as well as Phase Ib clinical trial for colorectal and ovarian cancer; CTX-471, a monoclonal antibody product candidate that is in Phase I clinical trial for patients with solid tumors, such as small cell lung cancer and melanoma; and CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 for oncology area.
- Get a free copy of the StockNews.com research report on Compass Therapeutics (CMPX)
- 3 Defensive Plays Going on the Offensive
- Could This Cheap Energy Stock With A 7% Dividend Yield Be Right for Your Portfolio?
- Is This A Buyable Bottom For Braze, Inc Shares?
- The Zedge Hypergrowth Story Is Played Out
- What To Make Of Tesla Right Now
Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.